Entero Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Entero Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Entero Therapeutics Inc Strategy Report
- Understand Entero Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Entero Therapeutics Inc formerly First Wave BioPharma Inc, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). Its pre-clinical products include AZX1103 and AZX1101 which is a recombinant beta-lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.
Entero Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
MS1819: |
Exocrine Pancreatic Insufficiency associated with Chronic Pancreatitis and Cystic Fibrosis |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Acquisitions/Mergers/Takeovers | In March, the company merged with ImmunogenX. |
2023 | Contracts/Agreements | In December, the company entered into a non-binding term sheet to sell its Niclosamide program to treat patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions. |
2023 | Contracts/Agreements | In September, the company entered into an agreement with Sanofi to reacquire Capeserod stages of clinical development and to commercialize the product. |
Competitor Comparison
Key Parameters | Entero Therapeutics Inc | Johnson & Johnson | AbbVie Inc | Vertex Pharmaceuticals Inc | Protagonist Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Boca Raton | New Brunswick | North Chicago | Boston | Newark |
State/Province | Florida | New Jersey | Illinois | Massachusetts | California |
No. of Employees | 15 | 131,900 | 50,000 | 5,400 | 124 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
James Sapirstein | Chief Executive Officer; Chairman; President | Executive Board | 2019 | 61 |
Sarah Romano | Chief Financial Officer | Senior Management | 2022 | - |
James Pennington, M.D. | Chief Medical Officer | Senior Management | 2018 | 79 |
Amy Chandler | Vice President - Regulatory Affairs, QA and Compliance | Senior Management | - | - |
Dinesh Srinivasan, Ph.D. | Vice President - Translational Research | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer